Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib second-line treatment study in advanced clear-cell renal cell carcinoma after checkpoint inhibitor progression
2024-514479-16-00Phase 2Completed
- Sponsor
- Ipsen
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of cabozantinib in clear cell renal cell carcinoma (ccRCC) (2 cohorts), sponsored by Ipsen. Primary endpoint: Objective response rate in Cohort A. Started Oct 2019; status: completed.
02
Drugs
cabozantinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2024-514479-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514479-16-00.